Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of “Hold” by Brokerages

Pulmonx Corporation (NASDAQ:LUNG) has been given a consensus recommendation of “Hold” by the seven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.5833.

Several research firms recently issued reports on LUNG. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday. D. Boral Capital reiterated a “buy” rating and set a $14.00 target price on shares of Pulmonx in a report on Thursday, April 30th. Finally, Canaccord Genuity Group dropped their target price on Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, March 5th.

Pulmonx Stock Performance

Shares of Pulmonx stock opened at $1.25 on Friday. Pulmonx has a one year low of $1.13 and a one year high of $3.88. The firm has a market cap of $52.80 million, a price-to-earnings ratio of -0.96 and a beta of 0.28. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. The stock’s 50-day moving average is $1.39 and its 200-day moving average is $1.63.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.33). Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%.The business had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. Equities analysts predict that Pulmonx will post -1.13 earnings per share for the current fiscal year.

Institutional Trading of Pulmonx

Several institutional investors and hedge funds have recently bought and sold shares of LUNG. ExodusPoint Capital Management LP bought a new stake in Pulmonx during the fourth quarter worth about $4,312,000. Vestal Point Capital LP acquired a new position in Pulmonx during the third quarter worth approximately $1,345,000. Bank of America Corp DE increased its position in Pulmonx by 60.3% during the first quarter. Bank of America Corp DE now owns 1,166,826 shares of the company’s stock worth $1,505,000 after buying an additional 439,027 shares during the last quarter. Birchview Capital LP acquired a new position in Pulmonx during the fourth quarter worth approximately $554,000. Finally, Kotler Kevin acquired a new position in Pulmonx during the fourth quarter worth approximately $442,000. Institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.